Loading company…
VentriNova Inc. develops regenerative gene therapies for heart disease, including VN-100, a cyclin A2 gene therapy.
Founded in 2006 and based in New York, US, VentriNova Inc. is a biotechnology company developing regenerative medicines for heart disease. Its lead product, VN-100, is a vector-based gene therapy that delivers the cyclin A2 gene to cause cardiomyocyte division in adult heart tissue.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in